MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

48.3 -1.39

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

48.12

Max

49.34

Galvenie mērījumi

By Trading Economics

Ienākumi

34M

22M

Pārdošana

16M

165M

P/E

Sektora vidējais

42.009

37.257

Peļņas marža

13.598

Darbinieki

674

EBITDA

20M

38M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+10.2% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 3. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

634M

2.7B

Iepriekšējā atvēršanas cena

49.69

Iepriekšējā slēgšanas cena

48.3

Ziņu noskaņojums

By Acuity

34%

66%

105 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 13. okt. 21:45 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

2025. g. 13. okt. 21:07 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

2025. g. 13. okt. 17:03 UTC

Galvenie tirgus virzītāji

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

2025. g. 13. okt. 23:53 UTC

Tirgus saruna

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

2025. g. 13. okt. 23:39 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2025. g. 13. okt. 22:15 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 13. okt. 22:15 UTC

Tirgus saruna

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

2025. g. 13. okt. 21:57 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

2025. g. 13. okt. 21:36 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 13. okt. 21:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 13. okt. 21:36 UTC

Tirgus saruna

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

2025. g. 13. okt. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

2025. g. 13. okt. 21:06 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

2025. g. 13. okt. 20:52 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs to Acquire Industry Ventures for Up to $965M

2025. g. 13. okt. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 13. okt. 20:35 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Expects to Close Deal in 1Q

2025. g. 13. okt. 20:34 UTC

Iegādes, apvienošanās, pārņemšana

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

2025. g. 13. okt. 20:33 UTC

Iegādes, apvienošanās, pārņemšana

Industry Ventures Currently Manages $7B of Assets Under Supervision

2025. g. 13. okt. 20:32 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

2025. g. 13. okt. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

2025. g. 13. okt. 20:29 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs to Buy VC Firm Industry Ventures

2025. g. 13. okt. 19:05 UTC

Tirgus saruna

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

2025. g. 13. okt. 18:59 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025. g. 13. okt. 18:26 UTC

Tirgus saruna

Precious Metals Close at New Record Highs -- Market Talk

2025. g. 13. okt. 18:10 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 13. okt. 18:10 UTC

Tirgus saruna

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

2025. g. 13. okt. 17:05 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 13. okt. 17:05 UTC

Tirgus saruna

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

2025. g. 13. okt. 16:03 UTC

Iegādes, apvienošanās, pārņemšana

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

2025. g. 13. okt. 15:35 UTC

Tirgus saruna

Precious Metals Push Record Highs Further -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

10.2% augšup

Prognoze 12 mēnešiem

Vidējais 54 USD  10.2%

Augstākais 65 USD

Zemākais 43 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

3

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Neutral Evidence

Noskaņojums

By Acuity

105 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
help-icon Live chat